Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 plus carbon ion radiotherapy followed by surgical resection for borderline resectable and unresectable locally advanced pancreatic cancer
jRCTs031230335Phase 2Recruiting
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur in pancreatic adenocarcinoma (PDAC). Primary endpoints: Resection rate, R0 resection rate and 1 more. Started Sep 2023; status: recruiting.
02
Drugs
tegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCTs031230335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230335.